| 151 | NSRXNasus Pharma Ltd |
1,2 Mrd. $ |
-0,5% |
2025 |
| 152 | TECHBIO-TECHNE Corp |
1,2 Mrd. $ |
15,0% |
2026 |
| 153 | STVNStevanato Group S.p.A. |
1,2 Mrd. € |
11,8% |
2025 |
| 154 | TRLVTrulieve Cannabis Corp. |
1,2 Mrd. $ |
-9,9% |
2025 |
| 155 | SHCSotera Health Co |
1,2 Mrd. $ |
6,7% |
2025 |
| 156 | NVAXNovavax Inc |
1,1 Mrd. $ |
39,2% |
2025 |
| 157 | LKFTLakefront Biotherapeutics NV |
1,1 Mrd. € |
28,9% |
2025 |
| 158 | PBHPrestige Consumer Healthcare Inc. |
1,1 Mrd. $ |
17,5% |
2026 |
| 159 | EMBCEmbecta Corp. |
1,1 Mrd. $ |
8,8% |
2025 |
| 160 | ACADAcadia Pharmaceuticals Inc |
1,1 Mrd. $ |
36,5% |
2025 |
| 161 | LEGNLegend Biotech Corp |
1 Mrd. $ |
-28,8% |
2025 |
| 162 | TNDMTandem Diabetes Care Inc |
1 Mrd. $ |
-20,2% |
2025 |
| 163 | SNDLSNDL Inc. |
1 Mrd. CA$ |
-1,6% |
2025 |
| 164 | INNVInnovAge Holding Corp. |
989,7 Mio. $ |
-0,3% |
2026 |
| 165 | GHGuardant Health, Inc. |
982 Mio. $ |
-42,4% |
2025 |
| 166 | MDGLMadrigal Pharmaceuticals, Inc. |
958,4 Mio. $ |
-30,1% |
2025 |
| 167 | PNTGPennant Group, Inc. |
947,7 Mio. $ |
3,1% |
2025 |
| 168 | IONSIonis Pharmaceuticals Inc |
943,7 Mio. $ |
-40,4% |
2025 |
| 169 | USNAUsana Health Sciences Inc |
925,3 Mio. $ |
1,2% |
2025 |
| 170 | TLRYTilray Brands, Inc. |
915,5 Mio. $ |
-13,3% |
2026 |
| 171 | INSPInspire Medical Systems, Inc. |
912 Mio. $ |
15,9% |
2025 |
| 172 | ANIPAni Pharmaceuticals Inc |
883,4 Mio. $ |
8,9% |
2025 |
| 173 | BCRXBiocryst Pharmaceuticals Inc |
874,8 Mio. $ |
30,2% |
2025 |
| 174 | WRBYWarby Parker Inc. |
871,9 Mio. $ |
0,2% |
2025 |
| 175 | NEOGNeogen Corp |
870,4 Mio. $ |
-0,9% |
2026 |
| 176 | HRMYHarmony Biosciences Holdings, Inc. |
868,5 Mio. $ |
18,3% |
2025 |
| 177 | ARWRArrowhead Pharmaceuticals, Inc. |
829,4 Mio. $ |
-0,2% |
2025 |
| 178 | MYGNMyriad Genetics Inc |
824,5 Mio. $ |
-44,4% |
2025 |
| 179 | OFIXOrthofix Medical Inc. |
822,3 Mio. $ |
-11,2% |
2025 |
| 180 | CAICaris Life Sciences, Inc. |
812 Mio. $ |
-8,4% |
2025 |
| 181 | TLXTelix Pharmaceuticals Ltd |
803,8 Mio. $ |
-0,9% |
2025 |
| 182 | EVOEvotec SE |
797 Mio. € |
-24,6% |
2024 |
| 183 | USPHU S Physical Therapy Inc |
781 Mio. $ |
5,1% |
2025 |
| 184 | COLLCollegium Pharmaceutical, Inc |
780,6 Mio. $ |
8,1% |
2025 |
| 185 | ATECAlphatec Holdings, Inc. |
764,2 Mio. $ |
-18,8% |
2025 |
| 186 | CORTCorcept Therapeutics Inc |
761,4 Mio. $ |
13,1% |
2025 |
| 187 | PAIYYAesthetic Medical International Holdings Group Ltd |
755,7 Mio. CN¥ |
-2,6% |
2024 |
| 188 | IRTCiRhythm Holdings, Inc. |
747,1 Mio. $ |
-6,0% |
2025 |
| 189 | EBSEmergent BioSolutions Inc. |
742,9 Mio. $ |
7,1% |
2025 |
| 190 | RGENRepligen Corp |
738,3 Mio. $ |
6,6% |
2025 |
| 191 | NEONeogenomics Inc |
727,3 Mio. $ |
-14,9% |
2025 |
| 192 | PCRXPacira BioSciences, Inc. |
726,4 Mio. $ |
1,0% |
2025 |
| 193 | ASNDAscendis Pharma A/S |
720,1 Mio. € |
-31,7% |
2025 |
| 194 | AMPHAmphastar Pharmaceuticals, Inc. |
719,9 Mio. $ |
13,6% |
2025 |
| 195 | SUPNSupernus Pharmaceuticals, Inc. |
719 Mio. $ |
-5,4% |
2025 |
| 196 | AVNSAvanos Medical, Inc. |
701,2 Mio. $ |
-10,4% |
2025 |
| 197 | KNSAKiniksa Pharmaceuticals International, plc |
677,6 Mio. $ |
8,7% |
2025 |
| 198 | RAREUltragenyx Pharmaceutical Inc. |
673 Mio. $ |
-85,4% |
2025 |
| 199 | CRLBFCresco Labs Inc. |
655,8 Mio. $ |
-20,6% |
2025 |
| 200 | NVCRNovoCure Ltd |
655,4 Mio. $ |
-20,8% |
2025 |